New RP-HPLC Method Development and Validation for the Determination of Pazopanib Hydrochloride in Tablet Dosage Form

Rajesh Babu Y*, Appala Raju N

Department of Pharmaceutical Chemistry, Sultan UI-Uloom College of Pharmacy, Mount Pleasant, 8-2-249, road No.3, Banjara hills, Hyderabad, Telangana – 50034, India

Received: 31st Jan, 17; Revised: 16th Feb, 17; Accepted:10th March, 17 ; Available Online:25th March, 2017

ABSTRACT
The aim of this paper was to develop and validate the stability indicating RP-HPLC method for the determination of Pazopanib hydrochloride in bulk and pharmaceutical dosage forms. A simple, accurate, precise, sensitive and stability indicating RP-HPLC method has been developed for the determination of Pazopanib hydrochloride in bulk drug and pharmaceutical dosage form, in which separations are done using develosil C18, 5μm, 150 x 4.6mm i.d. column at a flow rate of 1.0mL/min with an injection volume of 20μL. The beer’s law was obeyed over the concentration range of 5 - 35μg/mL. The correlation coefficient was found to be 0.996 and it showed good linearity, reproducibility, precision in this concentration range. The % recovery values were found to be within the limits, which showed that the method was accurate. The LOD and LOQ were calculated using statistical methods. The % RSD values were less than 2. The developed method was successfully applied for determination of Pazopanib hydrochloride in pharmaceutical dosage form. The results obtained are in good agreement with those obtained by using the standard method.

Keywords: Pazopanib hydrochloride, Develosil, Stability indicating, Method Development, Validation.

INTRODUCTION
Pazopanib is presented as the hydrochloride salt, with the chemical name 5-[(4-[2,3-dimethyl-2H-indazol-6-yl) methylamino]-2 pyrimidinyl] amino]-2- methyl benzene sulfonamide mono hydrochloride. It has the molecular formula C23H23N3O2•HCl and a molecular weight of 473.99. Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit and PDGFR-β receptors. According to the literature survey, it was found that few analytical methods on HPLC, HPTLC, UPLC and UV Spectrophotometer were reported for the estimation of Pazopanib hydrochloride in bulk drug and formulations. Hence there is need to develop and validate an analytical method to estpazopanib hydrochloridee the drug. The objective of the proposed method is to develop simple, accurate, precise, stability indicating RP-HPLC method for the estpazopanib hydrochlorideeion of Pazopanib hydrochloride in pharmaceutical dosage form.

MATERIAL AND METHODS
Reagents and Chemicals

Pazopanib hydrochloride working standard was procured from Mylan Laboratories, Hyderabad, Telangana. Pazopanib hydrochloride 400 mg tablets (Votrient®) were purchased from local pharmacy. Purified water was obtained from Millipore system. Acetonitrile (HPLC grade) and potassium dihydrogen orthophosphate were obtained from Loba Chem, Mumbai, and Sd fine-Chem Ltd, Mumbai, respectively. All other chemicals used in the analysis were AR grade.

Instrumental and analytical conditions
The HPLC analysis was performed using a HITACHI L2130 with D Elite 2000 Software with Isocratic with UV-Visible Detector (L-2400). Column used was developsl C18, 5μm, 150 x 4.6 mm i.d. UV detection was performed at 268nm. The injection volume of sample was 20μL. An isocratic mobile phase containing Acetonitrile and 0.05M potassium dihydrogen orthophosphate buffer (30:70%v/v), at the pH 2.5 with O-phosphoric acid was carried out with the flow rate of 1.0mL/min. Column was maintained at room temperature.

Experimental Mobile Phase Preparation
Mixture of Acetonitrile and Phosphate buffer, pH 2.5 in the ratio of 30:70(%v/v) respectively was used.

Preparation of Standard Solution
Accurately weighed 50mg of Pazopanib hydrochlorideworking standard was transferred into 50mL volumetric flask. About 40mL of diluent (mobile phase) was added and sonicated to dissolve. The volume was...
made up with diluent and mixed. 0.1mL of this solution was diluted to 10mL with mobile phase and mixed.

Preparation of Sample Solution
Four capsules were weighed accurately and the average weight was calculated. Capsules were opened, fine powder was collected and equivalent to 50mg of Pazopanib hydrochloride sample was weighed and transferred into 50mL volumetric flask. 40mL of diluent was added and sonicated for 30min with intermediate shaking. Volume was made up with diluent. The above solution was centrifuged for 10min at 8000rpm. 0.1mL of this solution was diluted to 10mL with mobile phase and mixed. The solution was filtered through 0.45 µm filter.

Method Development
Table 1: Data of System Suitability Parameter.

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Parameter</th>
<th>Limit</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Resolution</td>
<td>Rs &gt; 2</td>
<td>9.15</td>
</tr>
<tr>
<td>2</td>
<td>USP Tailing</td>
<td>T ≤2</td>
<td>0.12</td>
</tr>
<tr>
<td>3</td>
<td>USP plate count</td>
<td>N &gt; 2000</td>
<td>3246</td>
</tr>
</tbody>
</table>

Table 2: Result of different parameters.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Method Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specificity</td>
<td>Regression equation, y=mx+c</td>
</tr>
<tr>
<td>Linearity</td>
<td>Correlation coefficient (r)</td>
</tr>
<tr>
<td>Accuracy</td>
<td>Level I (80%)</td>
</tr>
<tr>
<td>(recovery)</td>
<td>Level II (100%)</td>
</tr>
<tr>
<td>n=3</td>
<td>Level III (120%)</td>
</tr>
<tr>
<td>Precision (%RSD) n=5</td>
<td>0.76</td>
</tr>
<tr>
<td>Ruggedness (%RSD) n=5</td>
<td>0.56</td>
</tr>
<tr>
<td>Limit of Detection (LOD)</td>
<td>0.341μg/mL</td>
</tr>
<tr>
<td>Limit of Quantitation (LOQ)</td>
<td>1.023μg/mL</td>
</tr>
<tr>
<td>System</td>
<td>USP Plate Count</td>
</tr>
<tr>
<td>Suitability</td>
<td>USP Tailing</td>
</tr>
</tbody>
</table>

A develosil C18, 5μm, 150 x 4.6 mm i.d as a stationary phase with a mobile phase of Acetonitrile and Phosphate buffer, pH 3.1 (25:75) at a flow rate 1.0mL/min and a detection wavelength of 268nm afforded the best separation of drug. The standard solution and sample solution prepared as above were injected into the 20μL loop and the chromatograms were recorded as shown in the “Fig. 2” and “Fig. 3” respectively. The retention time of drug, Pazopanib hydrochloride was found to be 2.67 mins. The amount of drug present in sample was calculated.

Method Validation
The proposed stability indicating method has been developed and validated for the determination of Pazopanib hydrochloride in pharmaceutical dosage forms. According to International Conference on Harmonization (ICH) guidelines13-14, validation of the method was carried out by using specificity, accuracy, linearity, suitability, LOD, LOQ, precision and stability studies.

System suitability
A standard solution was prepared by using Pazopanib hydrochloride working standard as per test method and was injected 5 times into the HPLC system. The system suitability parameters were evaluated from the Resolution, USP tailing and USP plate count values obtained from standard chromatograms as shown in Table 1.

Specificity
Specificity was evaluated by injecting standard solution and placebo solution individually into HPLC system.

Linearity of test solution
A series of solutions are prepared from standard stock solution at concentration levels from 05-35μg/ml for Pazopanib hydrochloride.

Accuracy
Drug assay was performed in triplicate as per test method with equivalent amount of drugs into each volumetric flask for each spike level to get the concentration of drugs equivalent to 80%, 100% and 120% of the labeled amount as the test method.

Precision
Repeatability
Repeatability of method was evaluated by calculating the %RSD of peak areas of five replicate injections for the standard concentration (10ppm) of drug.

Ruggudness
The ruggedness was also evaluated by analyzing five samples of drug by two analysts in the same laboratory using different HPLC systems.

Limit of Detection and Limit of Quantitation
The parameters LOD and LOQ were determined on the basis of standard deviation and slope of the regression equation.

Forced degradation studies
The forced degradation study was performed to determine the specificity and stability indicating property of developed method. The drug was deliberately subjected to stress conditions such as acidic condition, alkaline condition, oxidation condition and thermal condition. All the solutions for degradation were prepared by dissolving drug in diluent to get an initial concentration of 1mg/mL and filtered. Acid decomposition was carried out in 1N hydrochloric acid and alkaline degradation was conducted using 1N sodium hydroxide and kept aside for 24 hours. Solutions for oxidative degradation were prepared using 3% hydrogen peroxide at a concentration of 1mg/mL of Pazopanib hydrochloride and kept aside for 24 hours. For thermal degradation study, the drug solution 1mg/mL was

Figure 5: Linearity plot of Pazopanib hydrochloride.
Table 3: Forced degradation studies of Pazopanib hydrochloride

<table>
<thead>
<tr>
<th>Stress conditions</th>
<th>Drug recovered (%)</th>
<th>Drug decomposed (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard drug</td>
<td>100.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Acidic hydrolysis</td>
<td>62.56</td>
<td>37.44</td>
</tr>
<tr>
<td>Alkaline hydrolysis</td>
<td>98.32</td>
<td>1.68</td>
</tr>
<tr>
<td>Oxidative degradation</td>
<td>98.79</td>
<td>1.21</td>
</tr>
<tr>
<td>Thermal degradation</td>
<td>98.36</td>
<td>1.64</td>
</tr>
</tbody>
</table>

Heated in calibrated oven at 80°C for 8 hours, cooled and used. These solutions are injected into the HPLC system and values were noted.

RESULTS AND DISCUSSION

Selection of detection wavelength

From the UV spectrum, suitable wavelength considered for monitoring the drug was 268nm as shown in “Fig. 4”. A stability indicating RP-HPLC method was developed by using a Develosil C18 (150mm × 4.6mm, 5µm particle size) as a stationary phase with a mobile phase of Acetonitrile and Phosphate buffer, pH 2.5 (30:70) at a flow rate 1.0mL/min and a detection wavelength of 268nm afforded the best separation of drug. The injection volume is 20µL and retention time for Pazopanib hydrochloride is 2.67mins. The method was validated according to ICH guidelines for various parameters like accuracy, precision, linearity, specificity, ruggedness, LOD, LOQ and stability studies. Linearity was obtained in the concentration range of 0.5-35µg/mL with correlation coefficient (r) of 0.999. The %recovery was found to be 99.74%. The %RSD for precision was found to be 0.76 and for ruggedness it was found to be 0.53.

CONCLUSION

A simple, precise, accurate, rapid, economical, stability indicating RP-HPLC method for estimation of Pazopanib hydrochloride has been developed and validated as per ICH guidelines. The proposed method shows good agreement with all validation parameters. The optimized methodology is precise, accurate, specific, rugged, and a linear relation is observed between the concentration and the result. The developed method can be used for the analysis of routine quality control sample.

REFERENCES

11. ICH, Q3A(R2) Impurities in New Drug Substances (Geneva, Oct. 2006).
12. ICH, Q3B(R2) Impurities in New Drug Products (Geneva, June 2006).